SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Rachel Carson

PatientRachel Carson
Date of birth1973-05-27
IdentifiersMRN HR-ML041-SYN; SSN (made up) 000-41-5068
Document date2026-09-08
AuthorMargaret Vance-Okonkwo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Monitoring visit at the start of the fourth ribociclib cycle. [S]

History of Present Illness

Ms. Carson is twelve weeks into letrozole and starts her fourth cycle of ribociclib today. The oncology blood tests at about day 14 of the first cycle and on schedule since have shown neutrophils between 1.3 and 1.7, with normal liver tests and electrolytes; the neutrophil count was 1.2 at her sick visit in July, without fever, and she has had no fever since. The ECG planned for about day 14 of the first cycle was not done: she was away on the coast that week for field work and the ECG was not rebooked with her blood test. It was done at the start of the second cycle, four weeks after starting: QTcF 426 ms. She has mild morning knee stiffness for about ten minutes, eased by walking, and occasional night hot flashes. She is finishing the draft of her book this month. [S]

ElementDetail
Interval changeCycles 1 to 3 of ribociclib completed at full dose; viral rhinosinusitis in July
Oncology resultsNeutrophils 1.3 to 1.7; liver tests and electrolytes normal; QTcF 426 ms at the start of cycle 2
Side effectsMild knee stiffness and night hot flashes
AdherenceNo missed doses by her diary
WorkFinishing the draft of her book

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy good
CardiovascularNegativeNo palpitations, fainting, or chest pain
GastrointestinalNegativeNo nausea, diarrhea, or indigestion
MusculoskeletalPositiveMorning knee stiffness for about ten minutes; no bone pain
GenitourinaryNegativeNo vaginal bleeding
IntegumentaryNegativeNo rash; radiation skin settled
PsychiatricNegativeMood good; PHQ-9 3

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healingOne capsule once daily before breakfastOral route2026-01-19 to 2026-04-03completedS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2025-06-02activeS
Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five yearsOne tablet once dailyOral route2026-06-15activeS
Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three yearsTwo tablets once daily on days 1 to 21 of each 28-day cycleOral route2026-06-15activeS
Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three yearsOne infusion every six monthsIntravenous route2026-06-15activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-06-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-08Body height163cmS
2026-09-08Body weight59.6kgS
2026-09-08Body mass index (BMI) [Ratio]22.4kg/m2S
2026-09-08Systolic blood pressure118mm[Hg]S
2026-09-08Diastolic blood pressure74mm[Hg]S
2026-09-08Heart rate72/minS
2026-09-08Respiratory rate14/minS
2026-09-08Body temperature36.6CelS
2026-09-08Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-08Hemoglobin [Mass/volume] in Blood12.5g/dL12-15.5 g/dLNormalS
2026-09-08Leukocytes [#/volume] in Blood by Automated count3.410*3/uL4-11 10*3/uLLowS
2026-09-08Neutrophils [#/volume] in Blood by Automated count1.610*3/uL1.8-7.7 10*3/uLLowS
2026-09-08Platelets [#/volume] in Blood by Automated count19210*3/uL150-400 10*3/uLNormalS
2026-09-08Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-09-08Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L<=33 U/LNormalS
2026-09-08Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L<=32 U/LNormalS
2026-09-08Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL<=1.2 mg/dLNormalS
2026-09-08Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-09-08Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.4 mg/dLNormalS
2026-09-08Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-09-0825-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2026-09-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-09-08; see the Vital Signs section. [S]

SystemFinding
GeneralWell
BreastsLeft breast mildly firm after radiation; no masses. Right breast normal
Lymph nodesNo axillary, supraclavicular, or cervical nodes
ExtremitiesArm circumference 25.5 cm on each side; knees with mild crepitus and no effusion
AbdomenSoft; liver not enlarged
EyesNo jaundice

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1960 breast cancer, which was not disclosed to heractiveconfirmed C50.412S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy bookedresolvedconfirmed N63.21S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D).
Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure plannedresolvedconfirmed K26.9S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date.
Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shoreactiveconfirmed M17.0S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private.
Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17activeconfirmed C77.3S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used.
Long-term use of letrozole as adjuvant endocrine therapy, with ribociclib for three yearsactiveconfirmed Z79.811S — Synthetic treatment status.
Low bone mass (osteopenia) on baseline DXA before letrozole: lumbar spine T-score -1.8, femoral neck -1.3; 10-year major osteoporotic fracture risk about 7 percent (FRAX); vitamin D insufficiencyactiveconfirmed M85.80S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor.
Acute viral rhinosinusitis for five days while on ribociclib, with expected grade 2 neutropenia (absolute neutrophil count 1.2) and no fever; resolved with saline irrigationresolvedconfirmed J01.90S — Synthetic common illness; it echoes the sinus infection among her documented illnesses, which the sources do not date, and is not linked to that claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count on ribociclibEvery 2 weeks for 2 cycles, then at the start of the next 4 cyclesCompleted todayWhite cells 3.4, neutrophils 1.6 (grade 1), hemoglobin 12.5, platelets 192; earlier oncology counts 1.3 to 1.7
LaboratoryLiver tests on ribociclibEvery 2 weeks for 2 cycles, then at the start of the next 4 cyclesCompleted todayALT 31, AST 29, bilirubin 0.7; all earlier results normal
LaboratoryElectrolytes on ribociclibAt the start of each of the first 6 cyclesCompleted todayPotassium 4.1, magnesium 2.0, calcium 9.5
Medication safetyECG at about day 14 of the first cycleDay 14 of cycle 1DeferredMissed, a deviation from the protocol: she was away for field work and the ECG was not booked with her blood test. It was done at the start of cycle 2 instead, QTcF 426 ms, normal, so no harm resulted. Corrective action: the oncology scheduler now books ECGs with the blood tests and confirms by telephone; any dose change or new QT-prolonging drug will prompt a repeat ECG
Medication safetyInteraction reviewWith every new medicineCompleted todayNo new medicines; the July illness was treated without antibiotics
Medication safetyZoledronic acid: kidney function before the next infusionBefore each infusionCompleted todayCreatinine 0.8; next infusion in December
LaboratoryCalcium and vitamin D adequacyOngoing on an aromatase inhibitorCompleted today25-hydroxyvitamin D 34 ng/mL on replacement
ExaminationAromatase inhibitor joint pain and musculoskeletal reviewEvery visitCompleted todayMild morning knee stiffness, slightly longer than at baseline
SurveyVasomotor and vaginal symptomsPeriodically on endocrine therapyCompleted todayOccasional night hot flashes; no treatment wanted
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted today25.5 cm on each side; no swelling
ExaminationCancer-related history and physical examinationEvery 3 to 6 months for the first 3 yearsCompleted todayNo signs of recurrence
SurveyDepression screen (PHQ-9)At periodic intervalsCompleted todayPHQ-9 3
ImagingMammogram after breast-conserving treatment6 to 12 months after radiation, then yearlyDueFrom late November
LaboratoryRoutine tumor markers and body imagingNot recommended without symptomsNot indicatedNone ordered
Self-managementActivity, alcohol, and workEvery visitCompleted todayWalking about 150 minutes a week; rare alcohol; writing most mornings

Goal progress:

Guideline basis: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026); Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Oncology blood tests at the start of cycles 5 and 6. Adult preventive visit next month. Zoledronic acid in December. Mammogram from late November. Next scheduled visit 2026-10-13: adult preventive visit. [S]